Overview of Uniprim

Property	Description
Active Ingredients	Sulfadiazine and Trimethoprim
Form	Oral Powder or Premix for medicated feed
Pharmacological Class	Potentiated Sulfonamide Antibiotic
General Purpose	Systemic Anti-infective Agent
Origin	Synthetic

What Type of Medicine is Uniprim?

Uniprim is a broad-spectrum, synthetic antibacterial agent recognized as a potentiated sulfonamide antibiotic specifically formulated for veterinary use, primarily in equine medicine. This entity is a combination product, defined by its two synergistic active ingredients: Sulfadiazine and Trimethoprim. This pairing places it within the class of anti-infective agents known for their dual-action mechanism, which achieves a decisive systemic antibacterial activity.

This potent dual-component drug is prescription-only (Rx). The drug's classification establishes it as a powerful anti-infective designed to act systemically when treating a patient, such as an infected horse, for general bacterial concerns, supporting the need for professional oversight.

Composition and Synergistic Action

The composition of Uniprim involves two chemically distinct synthetic small molecule agents that work together through a potent synergistic mechanism. The combination relies on the sequential blockade of bacterial metabolism to disrupt the critical bacterial folic acid pathway. Pharmacological studies have consistently supported the principle that combining Sulfadiazine (which blocks an early step) with Trimethoprim (which blocks a later step) dramatically enhances the overall efficacy.

This strategic attack on two separate points of the pathway achieves a confirmed bactericidal (bacteria-killing) effect, which is substantially stronger than the typically bacteriostatic (growth-inhibiting) effect of either ingredient used alone.

Preparation Forms and General Anti-Infective Purpose

Uniprim is designed for oral delivery, generally available as an Oral Powder or a Premix for medicated feed. These pharmaceutical preparations are structured to facilitate consistent and non-invasive oral administration. A key differentiating feature is that the powder is often formulated to be palatable to ensure easier acceptance by the animal.

The primary function of this preparation is its extensive systemic antibacterial activity, leveraging its unique composition to serve as a reliable anti-infective agent. Its general use is centered on treating established infections that require prompt elimination of susceptible pathogens throughout the animal's system.

What side effects are possible with Uniprim?

Possible Side Effects and Safety Information

The official safety documentation for the potentiated sulfonamide combination (Sulfadiazine and Trimethoprim) lists potential adverse reactions across several major physiological systems, organizing the risk profile by the affected body parts.

Documented Adverse Reactions and Safety Patterns

The safety profile includes potential serious adverse reactions, such as hepatitis (liver inflammation) and non-regenerative anemia, which represents a severe effect on the blood system. Other documented effects on the blood and lymphatic system include leukopenia and thrombocytopenia.

Adverse reactions involving the nervous system may include ataxia (incoordination), depression, and convulsions. Hypersensitivity reactions affecting the skin and immune system are also listed, manifesting as conditions like facial swelling and urticaria (hives).

Duration-Related Risk and Contraindications

Official safety notes define a temporal risk pattern, specifically associating blood dyscrasias (disorders of blood components) with long-term use of the medication. The safety of the product is formally constrained by specific contraindications related to pre-existing health conditions.

The medication is contraindicated for any individual with a known hypersensitivity to either Sulfonamide or Trimethoprim components. Furthermore, it should not be administered to individuals who present with established blood dyscrasias or pre-existing marked liver damage, as these conditions increase the potential for serious adverse reactions. This structure highlights clinically important events and defines safety boundaries based on pre-existing health status.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documents describe specific clinical manifestations and mandated actions related to an overdose of the active ingredients, Sulfadiazine and Trimethoprim. Acute overdose may present with documented signs that include nausea, vomiting, loss of appetite, confusion, fever, and loss of consciousness. More severe, life-threatening outcomes formally listed in prescribing information include renal failure, fulminant hepatic necrosis, and serious blood disorders such as aplastic anemia and agranulocytosis. Chronic or prolonged high-dose exposure is associated with signs of folate deficiency, which may lead to severe hematologic toxicity. The regulatory profile specifically notes that an overdose increases risk for patients with pre-existing impaired renal function.

Immediate Emergency Actions

When an overdose is suspected, official guidance mandates that users seek immediate medical attention. This action is also required at the first appearance of serious symptoms, such as jaundice or a developing skin rash. Management for overdose is defined as symptomatic and supportive treatment due to the fact that no specific antidote is known. Procedures documented include the need for forced fluid administration and potential administration of folinic acid to manage established hematologic effects. Continuous observation and monitoring of blood counts are required for managing this systemic toxicity and ensuring the patient's stability.

Therapeutic Uses of Uniprim

What Uniprim Treats: Main Uses and Benefits

Uniprim is a prescription anti-infective commonly utilized to provide systemic antibacterial support for horses experiencing acute, widespread bacterial disease. This approach is applied when the patient exhibits symptoms related to systemic imbalance, such as fever, or localized discomfort arising from infection. It is primarily relevant for conditions including Acute Strangles, bacterial infections of the respiratory tract (such as bacterial pneumonia), infections of the urogenital system, and infected wounds or abscesses.

When applied to address these acute symptomatic episodes, the therapeutic benefit is support for the reduction of the bacterial load, which helps manage distressing manifestations like coughing, labored breathing, or purulent discharge. The medication is commonly used during phases when symptoms become more noticeable and systemic control is needed.

“It is commonly used across conditions presenting with acute episodes where systemic antibacterial intervention is required.”

Quick Fact: Relief for Systemic and Localized Discomfort

The medication is relevant for easing symptoms that create noticeable physiological strain, supporting the patient during difficult episodes of heightened infection.

Regulatory References

NIH DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Uniprim — Official Regulatory Information

Category	Official Regulatory Status
Populations for whom use is allowed	Horses (Target species) and Foals (Specifically documented as "well tolerated").
Populations for whom use is not recommended	Pregnant Mares (Use not established) and Lactating Mares (Safety not established). Breeding Horses (Safe use not evaluated).
Populations for whom use is contraindicated	Horses with a history of sulfonamide sensitivity, marked liver parenchymal damage, or blood dyscrasias.
Age-related eligibility rules	Foals are specifically noted as well tolerated. No explicit non-eligibility rule is cited for older horses.
Condition-specific eligibility rules	Contraindicated in marked liver parenchymal damage or blood dyscrasias.
Pregnancy and lactation eligibility status	Not established (Pregnancy and Lactation).
Eligibility-related restrictions	Horses intended for human consumption are strictly excluded from use ("Do not use in horses intended for human consumption").

Eligibility Classifications (High-Level)

Category	Official Regulatory Wording / Classification
Eligibility severity classification	Contraindicated (Highest severity exclusion) and Not Established (Use status for life stages).
Regulatory basis	FDA and Health Canada regulatory labeling.
Eligibility-context constraints	End-Use Restriction (Food Safety Warning) and Comorbidity (Liver, Blood, Sensitivity).

Resulting Eligibility Structure

Official eligibility statements:

Uniprim is officially indicated for use in horses and is documented as well tolerated by foals.
The medicine is contraindicated in horses with known sulfonamide sensitivity, marked liver parenchymal damage, or blood dyscrasias.
Use in pregnant mares is not established, and the product is not recommended for horses intended for human consumption.

Connection to the overall eligibility profile

The official regulatory profile defines the eligible population as horses, with specific documentation confirming suitability for foals. Absolute prohibitions, classified as contraindications, exclude animals with pre-existing conditions such as blood disorders or liver damage. Official labeling further restricts its use in pregnant mares, and absolutely prohibits its use in any horse intended for the human food chain.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interactions and constraints for this potentiated sulfonamide combination. These statements describe how the drug combination may be affected by or may affect other co-administered medicinal products.

Classification	Documented Interaction Profile
Formal Contraindication	The product is formally contraindicated in patients with marked liver parenchymal damage or blood dyscrasias. Co-administration with PABA-ester local anaesthetics (e.g., Procaine) is restricted due to the risk of pharmacodynamic antagonism leading to reduced efficacy.
High-Risk Combinations	Co-administration of the potentiated sulfonamide class with alpha2-adrenergic agonists, such as Detomidine or Xylazine, is associated with a severe risk of cardiac dysrhythmias and hypotension [Veterinary Monographs].
Exposure Modification	Substances that reduce systemic exposure include Antacids, which may inhibit absorption, and other acidic drugs that may displace the sulfonamide component from plasma protein binding sites.
Metabolic Interference	The sulfonamide component may act as a microsomal enzyme inhibitor, leading to altered clearance and potential accumulation of co-administered drugs like Phenytoin [Veterinary Monographs]. Co-administration with oral anticoagulants (e.g., Warfarin) may result in increased clotting time.
Timing Requirements	An administration separation of 2–3 hours is required when co-administering with Antacids. Water should be readily available during therapy as a necessary procedural constraint [NIH DailyMed].

These official statements classify the constraints, requirements, and risks associated with concurrent administration to structure the drug’s regulatory interaction profile.

Mechanism of Action

Uniprim acts by executing a sequential, double-blockade of the core bacterial metabolic pathway required for synthesizing tetrahydrofolic acid (THFA). Sulfadiazine competitively inhibits the DHPS enzyme, while Trimethoprim non-competitively inhibits the downstream DHFR enzyme, which establishes specific targeting of the microbial machinery. This combined, two-step inhibition prevents the synthesis of THFA, which is necessary for the bacteria to produce purines and thymidine, the core building blocks of DNA and RNA. The resulting metabolic collapse is characterized by bactericidal activity, resulting in the rapid cessation of replication and death of susceptible bacterial cells. The drug exhibits high selectivity because host cells use pre-formed folates, rendering the target pathway irrelevant, and the host's DHFR is less sensitive to Trimethoprim. This mechanism is functionally constrained, however, by resistant bacteria that can overproduce the PABA substrate or utilize modified target enzymes, which reduces the inhibitory effect at the molecular level.

Dosage and Administration Information

How to Use Uniprim: Administration Guidelines

Uniprim, a combination of Sulfadiazine and Trimethoprim designed as an Oral Powder for horses, is administered according to a weight-based protocol.

Administration and Dosage Schedule

Administration is exclusively by the oral route, with the powder intended to be mixed into a small quantity of palatable feed. The recommended single daily dose is calculated based on the animal’s body mass, requiring 3.75 g of Uniprim Powder for every 110 lbs (50 kg) of body weight. This amount delivers 30 mg/kg of the combined active ingredients daily.

To ensure dosage accuracy, it is recommended to use gentle agitation when scooping the powder, as product settling may occur. Water should be readily available to the animal during the entire course of treatment.

Course Duration and Continuation Logic

The typical duration of use is established at 5 to 7 days. The protocol specifies that for acute infections, administration should be continued for 2 or 3 days after clinical signs have subsided. This conditional duration ensures the full course is completed as designed. If no clinical improvement is observed after 3 to 5 days of use, the guidelines indicate a reevaluation of the diagnosis. The oral powder may also be used as follow-up therapy after an initial course of intravenous administration, if necessary.

Recent Clinical Evidence

Uniprim: Recent Clinical Evidence

Uniprim is a veterinary-approved antibiotic that combines trimethoprim and sulfadiazine. This fixed-ratio combination is utilized for its potent systemic antibacterial action against a range of susceptible bacterial strains.

Approved Indications and Efficacy

The approved uses for this combination drug focus exclusively on the control of specific bacterial infections in horses. Approved indications, based on regulatory filings and clinical data, include:

Respiratory Tract Infections
Acute Strangles (an upper respiratory tract infection)
Acute Urogenital Infections (such as urinary tract infections)
Wound Infections and Abscesses

Clinical trial results indicate that the drug led to a reduction in the severity and duration of symptoms associated with these conditions, supporting its use as a therapeutic option when susceptible organisms are confirmed. Data from the development program, which primarily enrolled adult horses, showed a measured response rate consistent with the drug's intended action.

Variability and Ongoing Research

In major clinical trials, response rates were observed to vary. Studies suggest that some animals may experience a limited or non-response, which is a subject of ongoing veterinary research. The focus includes identifying factors that may predict an individual animal's likely response and exploring mechanisms of acquired bacterial resistance to the combined components.

Investigational Context

As of the current understanding of the veterinary pharmaceutical landscape, this combination drug is specifically formulated and approved for use in horses. While the individual components (trimethoprim and sulfadiazine) are studied in other contexts, the product Uniprim has no non-veterinary regulatory approvals, and evidence regarding its use beyond the approved equine indications is not available in the public domain.

Frequently Asked Questions (FAQ)

Common questions about Uniprim (FAQ)

Q: What are the most commonly reported side effects people mention when taking Uniprim?

Official documents describe potential adverse reactions affecting various body systems. Documented effects include those on the blood (such as anemia and leukopenia) and the nervous system (such as ataxia and convulsions). The official documentation generally lists these potential effects but does not typically classify them by their frequency (for example, as 'most common').

Q: Does Uniprim have a black box warning from the FDA?

According to the official product labeling issued by the U.S. Food and Drug Administration (FDA), Uniprim does not currently include a Black Box Warning.

Q: What official studies are most frequently cited regarding Uniprim?

Regulatory documents include a summary of clinical trial results that were used to support the drug's approved uses in horses. Specific study identifiers and technical data may be listed in the clinical studies or references section of the full official label.

Q: Are there specific symptoms that require contacting a health professional while on Uniprim?

Official information notes the potential for serious adverse reactions, such as signs related to hepatitis or blood dyscrasias, which are severe effects on the liver and blood system. Furthermore, official instructions state that the diagnosis requires re-evaluation by a professional if no clinical improvement is observed after three to five days of use.

Q: How quickly should I expect to notice the effects of Uniprim?

The official product instructions describe the conditions for re-evaluation based on the clinical response. Specifically, the diagnosis is required to be re-evaluated if no clinical improvement has been observed after three to five days of using the medicine.

Q: Is Uniprim safe to take during pregnancy, according to official documents?

Official documentation is clear that the use of Uniprim in pregnant mares has not been established. This means its safety during pregnancy has not been evaluated according to regulatory requirements.

Q: Is Uniprim the same type of medicine as other common treatments for this condition?

Uniprim is officially classified as a potentiated sulfonamide antibiotic. This classification defines it as a combination drug with a unique dual-action mechanism targeting susceptible bacterial infections. Its classification defines its unique chemical class and mechanism of action.

Q: Does Uniprim cause changes in mood or sleep patterns?

Official regulatory documents list potential adverse effects on the nervous system, including descriptions of depression and convulsions. The official safety information does not specifically list general sleep pattern changes or mood disturbances beyond depression.

Q: Is it true that Uniprim can affect blood tests?

The drug’s safety profile includes potential effects on the blood and lymphatic systems, such as non-regenerative anemia and leukopenia. It is also described that the sulfonamide component acts as an enzyme inhibitor, which may potentially alter the clearance of certain other drugs.

Q: Does Uniprim require any special monitoring while being used?

The official label does not explicitly mandate routine laboratory monitoring (such as blood cell counts) during the typical short course of treatment. However, it does highlight the risk of blood dyscrasias (disorders of blood components) that is associated with use extending beyond the typical recommended duration.

Q: Can Uniprim be taken with other maintenance medications like blood pressure drugs?

The regulatory profile, specific to veterinary use in horses, describes interactions with specific classes of co-administered veterinary drugs. These include alpha2-adrenergic agonists (such as Xylazine) and oral anticoagulants (such as Warfarin).

Q: Do people typically continue to use Uniprim for a long time?

The recommended course of use is for a typical period of five to seven days. Official safety notes associate the risk of severe adverse effects, such as blood dyscrasias, with use that is considered long-term (extending beyond the typical recommended duration).

Q: Does the medicine come in different strengths or forms?

Uniprim is designed for oral delivery, available as an oral powder or premix for medicated feed. The dosage is calculated based on body weight, and the regulatory label details only the approved 48% concentration product.

Q: Does Uniprim have any known effects on fertility?

Official documentation states that the safe use of the product in breeding horses has not been evaluated by regulatory authorities.

Q: Is it necessary to avoid alcohol completely while taking Uniprim?

Uniprim is a veterinary-approved medicine formulated exclusively for use in horses. Its official regulatory information therefore does not provide data on interactions with human substances like alcohol.

Q: Are there any restrictions on driving or operating machinery while taking Uniprim?

Uniprim is a veterinary-approved medicine formulated exclusively for use in horses. Its regulatory information does not address safety or use restrictions related to human activities like driving or operating machinery.

Q: Can people who have liver problems use Uniprim?

Uniprim is a veterinary-approved medicine formulated exclusively for use in horses. Official regulatory documents for this product do not address safety or use considerations in human patients.

Q: Is there any information about Uniprim's use in children?

Uniprim is a veterinary-approved medicine formulated exclusively for use in horses. Its regulatory information does not address safety or use in human children.

Q: Can Uniprim affect the effectiveness of birth control pills?

Uniprim is a veterinary-approved medicine formulated exclusively for use in horses. Its regulatory information does not address safety or interactions with human medications like birth control pills.

Q: Do studies suggest Uniprim loses effectiveness over time?

Research is ongoing regarding the drug's effectiveness, including identifying factors that may predict an individual animal's likely response and exploring mechanisms of acquired bacterial resistance. Resistance is a known consideration in antibiotic therapy.

Q: Can someone with diabetes use Uniprim?

Uniprim is a veterinary-approved medicine formulated exclusively for use in horses. Its regulatory information does not address safety or use in human patients with conditions like diabetes.

Q: Is the use of Uniprim limited to a specific age range?

The official eligibility map documents that foals are well tolerated and defines the drug's use for horses. The official information does not cite a specific upper age limit for the product.

Q: What is the difference between an allergy and a side effect related to Uniprim?

Official documentation lists both Hypersensitivity reactions, which represent immune-mediated or allergic responses, and general Adverse Reactions, which are potential effects on various body systems like the blood or nervous system.

Q: Does Uniprim interact with commonly used over-the-counter pain relievers?

Uniprim is a veterinary-approved medicine formulated exclusively for use in horses. Its regulatory information does not address safety or interactions with commonly used human over-the-counter pain relievers.

Q: What are the official guidelines regarding Uniprim and kidney function?

Official contraindications cite marked liver damage and blood dyscrasias. While kidney function is not listed as a formal contraindication, the official instructions emphasize that water should be readily available during the entire course of treatment as a required procedural constraint.

Q: What information is usually found on the Patient Information Leaflet (PIL) for Uniprim?

The Patient Information Leaflet (PIL) or official label is designed to contain comprehensive information. This includes the drug's purpose, approved uses, potential side effects, and a list of specific contraindications and required precautions.

How should Uniprim be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines define specific conditions for storing and disposing of Uniprim Powder to maintain its stability and ensure safety.

Storage Conditions

Constraint	Requirement
Temperature	Store at or below 25 C (77 F).
Protection	Keep the container tightly closed and protect the powder from moisture.
Container	Store in the original container and in a secure, well-ventilated location.
Safety	KEEP OUT OF REACH OF CHILDREN and pets.

Disposal Instructions

Unused or expired Uniprim must be disposed of in accordance with local and national regulations. The product is not recommended for flushing down the sink or toilet; instead, disposal should occur through an approved waste disposal facility.

Uniprim